Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Takeda Sees Largest Earnings Gain In Six-Plus Years

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical registered its biggest stock market gain in six years after an analyst noted the Japanese firm was experiencing steady earnings. The Nikko Citigroup analyst also noted, however, that Takeda still does not have a successor for its Actos (pioglitazone hydrochloride) diabetes drug, whose patent is set to expire in 2011. He said Takeda is looking to its SYR-322 (alogliptin) type 2 diabetes drug and a joint-venture stomach ulcer drug to counter the expected decline in Actos sales, and has ample cash for mergers and acquisitions. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts